bioAffinity Technologies, Inc.
BIAFbioAffinity Technologies, Inc. in brief
bioAffinity Technologies, Inc. is a listed company in the Diagnostics and Research industry, based in San Antonio, Texas, USA. Its market value was $5 M on 28 October 2026, which makes it the 26,816th largest listed company in the world and the 4,391st largest in the USA on this site. In the year to December 2025 it had sales of $6 M and a net loss of $15 M. Its shares trade under the symbol BIAF (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
bioAffinity Technologies, Inc. timeline
- 2017
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2022
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 2 September 2022; shares registered for exchange trading on 23 August 2022.
- 2024
- 💰Record revenue of $9 millionFY2024, the highest of the 4 years on record.
Events of bioAffinity Technologies, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,407 (Dec 2022) · #5,273 (Jul 2023) · #4,446 (Jan 2024) · #2,440 (Mar 2026) · #4,158 (Aug 2026) · #4,314 (Oct 2026) · #4,393 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 1.0×
- Price / book
- 0.7×
- Free cash flow yield
- -174.2%
- Net margin (TTM)
- -279.3%
- Operating margin
- -171.6%
- Return on equity
- -211.8%
- Liabilities / assets
- 33.6%
- Revenue growth
- -34.2%
- R&D / revenue
- 22.4%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $6M | -34.2% | $-11M | $-15M | -242.0% |
| Dec 2024 | $9M | +18.5% | $-9M | $-9M | -96.6% |
| Dec 2023 | $8M | +14.5% | $-8M | $-8M | -100.5% |
| Dec 2022 | $7M | — | $-4M | $-8M | -118.1% |
| Dec 2021 | — | — | $-2M | $-6M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-9M | $0M | $-9M | $-8.66 | — |
| Dec 2024 | $-7M | $0M | $-7M | $-22.50 | — |
| Dec 2023 | $-6M | $0M | $-6M | $-0.91 | — |
| Dec 2022 | $-4M | $0M | $-4M | $-1.81 | — |
| Dec 2021 | $-2M | — | — | — | — |
Quarterly results
Latest quarter to Sep 2026: revenue $1M (-26.2% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 6, 20268-KCurrent reportResults of operations
- Nov 6, 202610-QQuarterly report · period to Sep 2026
- Oct 29, 20268-KCurrent reportOther events
- Oct 23, 2026DEF 14AProxy statement
- Oct 15, 20268-KCurrent reportOther events
- Oct 13, 20268-KCurrent reportOther events
- Oct 9, 20268-KCurrent reportMaterial agreement · Unregistered share sale · Other events
- Oct 8, 20268-KCurrent reportOther events
- Oct 6, 20268-KCurrent reportOther events
- Sep 30, 20268-KCurrent reportOther events
- Sep 22, 20268-KCurrent reportOther events
- Sep 17, 20268-KCurrent reportOther events
Official filings of bioAffinity Technologies, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $6 M
- Operating income
- $-11 M
- Net income
- $-15 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $11 M
- Total liabilities
- $4 M
- Total equity
- $7 M
As of December-2025
Top 14 institutional investors in bioAffinity Technologies, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | HRT Financial LP | 91,431 | New | 5.02% | $1 M | Nov 13, 2026 |
| 2 | Jane Street Group, LLC | 42,786 | New | 2.35% | $0 M | Nov 12, 2026 |
| 3 | Virtu Financial LLC | 16,742 | New | 0.92% | $0 M | Nov 17, 2026 |
| 4 | BlackRock, Inc. | 6,583 | New | 0.36% | $0 M | Nov 13, 2026 |
| 5 | Vanguard Capital Management LLC | 3,701 | New | 0.20% | $0 M | Nov 13, 2026 |
| 6 | UBS Group AG | 3,104 | New | 0.17% | $0 M | Nov 10, 2026 |
| 7 | Vanguard Fiduciary Trust Co | 2,071 | New | 0.11% | $0 M | Nov 13, 2026 |
| 8 | Allworth Financial LP | 666 | New | 0.04% | $0 M | Nov 17, 2026 |
| 9 | Tower Research Capital LLC (TRC) | 318 | New | 0.02% | $0 M | Nov 16, 2026 |
| 10 | Royal Bank Of Canada | 62 | New | 0.00% | $0 M | Nov 16, 2026 |
| 11 | IFP Advisors, Inc | 55 | New | 0.00% | $0 M | Oct 16, 2026 |
| 12 | Robinhood Markets, Inc. | 38 | — | 0.00% | $0 M | Nov 18, 2026 |
| 13 | Russell Investments Group, Ltd. | 1 | New | 0.00% | $0 M | Nov 6, 2026 |
| 14 | Pinnacle Financial Group, Inc. | 1 | — | 0.00% | $0 M | Nov 16, 2026 |
Mutual funds holding bioAffinity Technologies, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 28,059 | $0 M | 1.5% | <0.01% | −5.7% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 55,543 | $0 M | 3.1% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 7,639 | $0 M | 0.42% | <0.01% | +1575% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 6,517 | $0 M | 0.36% | <0.01% | +48% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 3,114 | $0 M | 0.17% | <0.01% | +418% | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 5 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at bioAffinity Technologies, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Timothy P. ZannesSecretary, EVP, Gen. Counsel | Grant or award | +8,641 | — | — | 54,765 | Form 4 |
| filed | Steven GirgentiExecutive Chairman, Director | Grant or award | +14,814 | — | — | 1.08 M | Form 4 |
| filed | James Michael EdwardsVP and CFO | Grant or award | +6,172 | — | — | 120,128 | Form 4 |
| filed | Maria ZannesPresident & CEO, Director | Grant or award | +37,037 | — | — | 280,359 | Form 4 |
| filed | Xavier Trinidad RevelesChief Operating Officer | Grant or award | +21,604 | — | — | 41,943 | Form 4 |
| filed | James Michael EdwardsVP and CFO | Grant or award | +100,000 | — | — | 113,956 | Form 4 |
| filed | Maria ZannesPresident & CEO, Director | Grant or award | +33,784 | — | — | 243,322 | Form 4 |
| filed | Peter S. KnightDirector | Grant or award | +33,784 | — | — | 117,455 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: bioAffinity Technologies, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-10-08 16:07 UTC, code LUDP, resumed 16:17 UTC
- 2026-09-17 16:26 UTC, code LUDP, resumed 16:31 UTC
- 2026-09-04 15:06 UTC, code LUDP, resumed 15:11 UTC
- 2026-09-01 13:40 UTC, code LUDP, resumed 13:45 UTC
- 2026-08-21 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 4,980 shares at $2.96
- : 4,301 shares at $3.51
- : 7,605 shares at $3.63
- : 71,087 shares at $5.64
- : 12,551 shares at $6.56
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
bioAffinity Technologies, Inc. scorecard#
Passes 3 of the 18 checks that could be worked out: strongest in valuation (2 of 5), weakest in growth (0 of 4). Fiscal year 2025; market cap of Oct 28, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median0.7×Price to book 0.7× against Diagnostics and Research's median of 3.7×.
- ✓Price to sales below its peers' median1.0×Price to sales 1.0× against Diagnostics and Research's median of 4.5×.
- ✗Free cash flow yield above 5%-174.2%Free cash flow is -174.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 4
- ✗Revenue grew in the newest year-34.2%Revenue down 34.2% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-3.7%-3.7% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-3.7%-3.7% a year against Diagnostics and Research's median of 3.6% (64 companies).
- ✗Earnings per share grew in the newest year-8.66 vs -22.50Diluted EPS -8.66 in fiscal 2025 against -22.50 the year before (report's currency).
- –Net income higher than five years earlierNet income of five years earlier is not on file.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 5
- ✗Profitable in the newest year-$15 MNet income -$15 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-171.6%-171.6% against Diagnostics and Research's median of -2.4% (66 companies).
- ✗Return on equity above 15%-301.8%-301.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✗Operating margin wider than three years earlier-171.6%-171.6% in fiscal 2025 against -58.1% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities2.6×Current ratio 2.60 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-9.99Z-score -9.99 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year326.0%Diluted shares up 326.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Diagnostics and Research, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from bioAffinity Technologies, Inc.'s statements, beside the median of Diagnostics and Research.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -171.6% | -2.4% | |
| Net margin | -242.1% | -3.6% | |
| Return on equity | -301.8% | -5.4% | |
| Revenue growth, 3 years a year | -3.7% | 3.6% | |
| Revenue growth | -34.2% | 6.6% | |
| Free cash flow margin | -152.4% | 4.7% |
4of 7on the Piotroski tests of financial strength
- Revenue fell 34.2% against the year before.
- Net loss of $15 million, the 5th loss-making year in a row.
- Free cash flow was negative: -$9 million.
- The share count rose 326.0% in the year.
bioAffinity Technologies, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 6,162−34.2%100% | 9,362+18.5%100% | 7,900+14.5%100% | 6,900r4.8—100% | — | |
| Cost of revenue | — | — | — | 0.5—0.0% | — | |
| Gross profit | — | — | — | 4.3—0.1% | — | |
| Research and development | 1,383−5.3%22.4% | 1,461−0.5%15.6% | 1,468+6.5%18.6% | 1,379r1,143+36.8%20.0% | 1,007—— | |
| Selling, general and administrative | 9,914−0.3%161% | 9,943+46.4%106% | 6,791+174%86.0% | 2,481r2,727+132%36.0% | 1,069—— | |
| Operating expenses | 16,734−8.6%272% | 18,315+74.3%196% | 10,506+162%133% | 4,016r4,015+82.0%58.2% | 2,207—— | |
| Operating income | −10,573—−172% | −8,953—−95.6% | −7,973—−101% | −4,011—−58.1% | −2,207—— | |
| Interest and finance income | 23+32.8%0.4% | 18−85.6%0.2% | 122+161%1.5% | 47+10916%0.7% | 0.4—— | |
| Interest expense and finance costs | 44−52.0%0.7% | 92+149%1.0% | 37−98.5%0.5% | 2,533+153%36.7% | 1,002—— | |
| Other non-operating income (expense) | −4,293—−69.7% | −75−231%−0.8% | 57—0.7% | −4,141—−60.0% | — | |
| Income before tax | −14,866—−241% | −9,028—−96.4% | −7,916—−100% | −8,152—−118% | −6,324—— | |
| Income tax | 44+278%0.7% | 12−44.5%0.1% | 21+754%0.3% | 2.5+26.1%0.0% | 2.0—— | |
| Net income including minority interests | — | — | 8,6000.0%109% | 8,600—125% | — | |
| Net income attributable to shareholders | −14,910—−242% | −9,040—−96.6% | −7,937—−100% | −8,154—−118% | −6,326—— | |
| Earnings per share, basic | -8.66—— | -22.50r-0.75—— | -0.91—— | -1.81—— | -2.36—— | |
| Earnings per share, diluted | -8.66—— | -22.50r-0.75—— | -0.91—— | -1.81—— | — | |
| Shares, weighted average (basic) | 1.7+326%— | 0.4r12−95.4%— | 8.7+94.4%— | 4.5+68.2%— | 2.7—— | |
| Shares, weighted average (diluted) | 1.7+326%— | 0.4r12−95.4%— | 8.7+94.4%— | 4.5—— | — | |
| Balance sheet | ||||||
| Cash and cash equivalents | 6,450+484%58.8% | 1,105−60.8%17.0% | 2,822−75.3%34.3% | 11,414+739%93.7% | 1,361—93.6% | |
| Receivables | — | — | — | 10—0.1% | — | |
| Inventory | 54+94.0%0.5% | 28+49.4%0.4% | 18+234%0.2% | 5.5—0.0% | — | |
| Other current assets | 520+22.9%4.7% | 423+31.8%6.5% | 321−39.6%3.9% | 532+599%4.4% | 76—5.2% | |
| Current assets | 7,565+181%69.0% | 2,695−32.2%41.4% | 3,973−66.8%48.3% | 11,962+732%98.2% | 1,438—99.0% | |
| Property, plant and equipment | 266−29.2%2.4% | 375−18.2%5.8% | 459+114%5.6% | 214+4528%1.8% | 4.6—0.3% | |
| Right-of-use (leased) assets | 334−27.8%3.0% | 463+25.0%7.1% | 370—4.5% | — | — | |
| Goodwill | 1,4040.0%12.8% | 1,4040.0%21.6% | 1,404—17.1% | — | — | |
| Other intangible assets | 717−7.5%6.5% | 775−7.0%11.9% | 833—10.1% | — | — | |
| Total assets | 10,961+68.3%100% | 6,514−20.8%100% | 8,222−32.5%100% | 12,182+738%100% | 1,453—100% | |
| Accounts payable | 762−22.8%7.0% | 987+63.2%15.2% | 605+75.3%7.4% | 345+49.8%2.8% | 230—15.9% | |
| Current liabilities | 2,906−6.4%26.5% | 3,105+38.1%47.7% | 2,248+97.4%27.3% | 1,139−91.3%9.3% | 13,040—897% | |
| Lease liabilities (non-current) | 203−40.7%1.9% | 342+20.9%5.3% | 283—3.4% | — | — | |
| Total liabilities | 3,683−5.8%33.6% | 3,912+16.2%60.1% | 3,366+196%40.9% | 1,139−91.4%9.3% | 13,200—908% | |
| Retained earnings | −68,554—−625% | −53,644—−824% | −44,604—−543% | −36,667—−301% | −28,513—−1962% | |
| Shareholders' equity | 7,278+180%66.4% | 2,602−46.4%39.9% | 4,855−56.0%59.1% | 11,043—90.7% | −15,791—−1087% | |
| Total liabilities and equity | 10,961+68.3%100% | 6,514−20.8%100% | 8,222−32.5%100% | 12,182+738%100% | 1,453—100% | |
| Shares outstanding | 0.3r4.5−42.2%— | 0.5r16−94.5%— | 9.4+12.1%— | 8.4+213%— | 2.7—— | |
| Cash-flow statement | ||||||
| Depreciation and amortization | 505−16.6%8.2% | 606+143%6.5% | 250+2351%3.2% | 10+111%0.1% | 4.8—— | |
| Share-based compensation | 671−32.2%10.9% | 990+32.2%10.6% | 749+201%9.5% | 249+478%3.6% | 43—— | |
| Cash from operating activities | −9,329—−151% | −7,265—−77.6% | −6,038—−76.4% | −4,071—−59.0% | −2,049—— | |
| Capital expenditure | −61—−1.0% | −79—−0.8% | −23—−0.3% | −220—−3.2% | — | |
| Acquisitions, net of cash acquired | — | — | −2,186—−27.7% | — | — | |
| Cash from investing activities | −61—−1.0% | −79—−0.8% | −2,209—−28.0% | −220—−3.2% | — | |
| Cash from financing activities | 14,734+162%239% | 5,628—60.1% | −345−102%−4.4% | 14,344+331%208% | 3,327—— | |
| Change in cash | 5,344—86.7% | −1,716—−18.3% | −8,592−185%−109% | 10,053+687%146% | 1,278—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 5,525−18.5%100% | 1,070−26.0%100% | 1,511+19.0%100% | 1,352−27.1%100% | 1,593*−27.8%100% | 1,446−38.5%100% | 1,269−47.1%100% | 1,854−23.0%100% | 2,208*−2.4%100% | 2,350—100% | 2,398—100% | 2,406—100% | 2,261r7,579*—100% | |
| Research and development | 1,474+5.3%26.7% | 389+17.7%36.4% | 362+16.1%23.9% | 350−4.8%25.9% | 374*−4.3%23.5% | 331+20.4%22.9% | 311−22.6%24.5% | 367−6.7%19.8% | 391*−9.7%17.7% | 274—11.7% | 402—16.8% | 394—16.4% | 433*—19.1% | |
| Selling, general and administrative | 11,897+21.4%215% | 2,760+24.9%258% | 2,859+29.1%189% | 3,242+32.2%240% | 3,037*+4.0%191% | 2,209−6.6%153% | 2,215−10.4%174% | 2,453+12.2%132% | 2,920*+31.9%132% | 2,365—101% | 2,473—103% | 2,186—90.8% | 2,214*—97.9% | |
| Operating expenses | 19,125+11.5%346% | 4,581+22.5%428% | 4,845+28.0%321% | 4,969+10.9%368% | 4,730*−8.2%297% | 3,739−13.5%259% | 3,785−15.6%298% | 4,481+3.0%242% | 5,154*+13.1%233% | 4,324—184% | 4,485—187% | 4,352—181% | 4,556r4,632*—202% | |
| Operating income | −13,599—−246% | −3,511—−328% | −3,335—−221% | −3,617—−268% | −3,137*—−197% | −2,293—−159% | −2,516—−198% | −2,627—−142% | −2,947*—−133% | −1,974—−84.0% | −2,088—−87.1% | −1,945—−80.8% | −2,342*—−104% | |
| Interest and finance income | 38+390%0.7% | 4.7+335%0.4% | 3.4+65.8%0.2% | 10+1750%0.7% | 20*+385%1.2% | 1.1−51.2%0.1% | 2.0−61.0%0.2% | 0.5−91.2%0.0% | 4.1*−66.5%0.2% | 2.2—0.1% | 5.2—0.2% | 6.1—0.3% | 12*—0.5% | |
| Interest expense and finance costs | 50−10.9%0.9% | 11+99.9%1.0% | 12+11.7%0.8% | 15−4.9%1.1% | 13*−47.8%0.8% | 5.4−75.2%0.4% | 10−53.0%0.8% | 15−34.2%0.8% | 25*−1.1%1.1% | 22—0.9% | 22—0.9% | 24—1.0% | 25*—1.1% | |
| Other non-operating income (expense) | −1,809—−32.7% | −1,766—−165% | −31—−2.1% | −14—−1.0% | 2.7*—0.2% | −2,755—−191% | −1,516—−119% | −25—−1.3% | −20*—−0.9% | −24—−1.0% | −17—−0.7% | −13—−0.5% | −28*—−1.3% | |
| Income before tax | −15,408—−279% | −5,277—−493% | −3,366—−223% | −3,631—−269% | −3,134*—−197% | −5,048—−349% | −4,032—−318% | −2,652—−143% | −2,967*—−134% | −1,998—−85.0% | −2,105—−87.8% | −1,958—−81.4% | −2,371*—−105% | |
| Income tax | — | — | — | — | 3.2*—0.2% | 3.2+24.3%0.2% | 29+435%2.3% | 8.7+137%0.5% | 0*−100%0.0% | 2.6—0.1% | 5.4—0.2% | 3.7—0.2% | 2.3*—0.1% | |
| Net income including minority interests | — | — | — | — | — | — | — | — | — | — | — | — | 14,844*—657% | |
| Net income attributable to shareholders | −15,411—−279% | −5,277—−493% | −3,366—−223% | −3,631—−269% | −3,137*—−197% | −5,051—−349% | −4,061—−320% | −2,660—−144% | −2,967*—−134% | −2,001—−85.1% | −2,110—−88.0% | −1,962—−81.5% | −2,373*—−105% | |
| Earnings per share, basic | — | -5.89—— | -0.64—— | -0.81—— | — | -71.05r-4.74—— | -5.07r-0.17—— | -4.80r-0.16—— | — | -4.84r-0.16—— | -0.19—— | -0.20—— | — | |
| Earnings per share, diluted | — | -5.89—— | -0.64—— | -0.81—— | — | -71.05r-4.74—— | -5.07r-0.17—— | -4.80r-0.16—— | — | -4.84r-0.16—— | -0.19—— | -0.20—— | — | |
| Shares, weighted average (basic) | 0.9+1161%— | 0.9+1161%— | 5.2+553%— | 4.5+730%— | — | 0.1r1.1−82.8%— | 0.8r24−93.0%— | 0.5r16−94.5%— | — | 0.4r12—— | 11—— | 9.9—— | — | |
| Shares, weighted average (diluted) | 0.9+1161%— | 0.9+1161%— | 5.2+553%— | 4.5+730%— | — | 0.1r1.1−82.8%— | 0.8r24−93.0%— | 0.5r16−94.5%— | — | 0.4r12—— | 11—— | 9.9—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2,550—33.8% | 2,550−66.7%33.8% | 2,430+203%31.9% | 3,098+597%39.0% | 6,450+484%58.8% | 7,669+914%66.4% | 803+0.2%16.9% | 445−81.9%8.0% | 1,105−60.8%17.0% | 757—11.5% | 801—12.0% | 2,453—30.5% | 2,822—34.3% | |
| Inventory | 109—1.4% | 109+209%1.4% | 82+87.3%1.1% | 78+101%1.0% | 54+94.0%0.5% | 35+38.9%0.3% | 44+47.7%0.9% | 39+309%0.7% | 28+49.4%0.4% | 25—0.4% | 30—0.4% | 9.5—0.1% | 18—0.2% | |
| Other current assets | 427—5.7% | 427−7.2%5.7% | 458+14.5%6.0% | 480+15.2%6.0% | 520+22.9%4.7% | 460+4.6%4.0% | 400+57.7%8.4% | 417+20.8%7.5% | 423+31.8%6.5% | 440—6.7% | 254—3.8% | 345—4.3% | 321—3.9% | |
| Current assets | 3,828—50.7% | 3,828−55.6%50.7% | 3,865+132%50.7% | 4,341+133%54.6% | 7,565+181%69.0% | 8,614+238%74.6% | 1,669−37.7%35.1% | 1,864−52.6%33.6% | 2,695−32.2%41.4% | 2,549—38.9% | 2,680—40.3% | 3,931—48.8% | 3,973—48.3% | |
| Property, plant and equipment | 362—4.8% | 362+19.5%4.8% | 314−10.7%4.1% | 247−35.4%3.1% | 266−29.2%2.4% | 303−27.5%2.6% | 351−21.8%7.4% | 382−17.1%6.9% | 375−18.2%5.8% | 418—6.4% | 449—6.7% | 461—5.7% | 459—5.6% | |
| Right-of-use (leased) assets | 731—9.7% | 731+98.9%9.7% | 769+92.4%10.1% | 336r651−22.2%4.2% | 334−27.8%3.0% | 367−25.6%3.2% | 400+23.1%8.4% | 432+24.1%7.8% | 463+25.0%7.1% | 494—7.5% | 325—4.9% | 348—4.3% | 370—4.5% | |
| Goodwill | 1,404—18.6% | 1,4040.0%18.6% | 1,4040.0%18.4% | 1,4040.0%17.7% | 1,4040.0%12.8% | 1,4040.0%12.2% | 1,4040.0%29.6% | 1,4040.0%25.3% | 1,4040.0%21.6% | 1,404—21.4% | 1,404—21.1% | 1,404—17.4% | 1,404—17.1% | |
| Other intangible assets | 673—8.9% | 673−8.0%8.9% | 688−7.8%9.0% | 702−7.7%8.8% | 717−7.5%6.5% | 731−7.4%6.3% | 746−7.3%15.7% | 761−7.1%13.7% | 775−7.0%11.9% | 790—12.1% | 804—12.1% | 819—10.2% | 833—10.1% | |
| Total assets | 7,554—100% | 7,554−34.6%100% | 7,619+60.4%100% | 7,945+43.2%100% | 10,961+68.3%100% | 11,546+76.2%100% | 4,751−28.6%100% | 5,547−31.1%100% | 6,514−20.8%100% | 6,552—100% | 6,656—100% | 8,049—100% | 8,222—100% | |
| Accounts payable | 949—12.6% | 949+0.9%12.6% | 970−17.1%12.7% | 836−39.5%10.5% | 762−22.8%7.0% | 941+20.2%8.1% | 1,170+37.9%24.6% | 1,382+260%24.9% | 987+63.2%15.2% | 783—11.9% | 848—12.7% | 384—4.8% | 605—7.4% | |
| Current liabilities | 2,533—33.5% | 2,533+7.4%33.5% | 2,681+3.6%35.2% | 3,185−6.7%40.1% | 2,906−6.4%26.5% | 2,360−5.3%20.4% | 2,588+11.3%54.5% | 3,415+92.8%61.6% | 3,105+38.1%47.7% | 2,491—38.0% | 2,326—34.9% | 1,772—22.0% | 2,248—27.3% | |
| Lease liabilities (non-current) | 596—7.9% | 596+149%7.9% | 638+133%8.4% | 545+76.8%6.9% | 203−40.7%1.9% | 239−36.3%2.1% | 274+17.8%5.8% | 308+19.5%5.6% | 342+20.9%5.3% | 375—5.7% | 233—3.5% | 258—3.2% | 283—3.4% | |
| Total liabilities | 3,639—48.2% | 3,639+37.6%48.2% | 3,850−44.1%50.5% | 4,284+4.3%53.9% | 3,683−5.8%33.6% | 2,644−22.9%22.9% | 6,887+114%145% | 4,108+47.1%74.1% | 3,912+16.2%60.1% | 3,431—52.4% | 3,223—48.4% | 2,792—34.7% | 3,366—40.9% | |
| Retained earnings | −80,828—−1070% | −80,828—−1070% | −75,551—−992% | −72,185—−909% | −68,554—−625% | −65,417—−567% | −60,366—−1271% | −56,305—−1015% | −53,644—−824% | −50,677—−773% | −48,677—−731% | −46,566—−579% | −44,604—−543% | |
| Shareholders' equity | 3,915—51.8% | 3,915−56.0%51.8% | 3,769—49.5% | 3,647r3,661+153%45.9% | 7,278+180%66.4% | 8,902+185%77.1% | −2,136−162%−45.0% | 1,439−72.6%25.9% | 2,602−46.4%39.9% | 3,121—47.6% | 3,433—51.6% | 5,257—65.3% | 4,855—59.1% | |
| Total liabilities and equity | 7,554—100% | 7,554−34.6%100% | 7,619+60.4%100% | 7,945+43.2%100% | 10,961+68.3%100% | 11,546+76.2%100% | 4,751−28.6%100% | 5,547−31.1%100% | 6,514−20.8%100% | 6,552—100% | 6,656—100% | 8,049—100% | 8,222—100% | |
| Shares outstanding | 1.2—— | 1.2−66.3%— | 6.8−76.2%— | 4.5−75.4%— | 0.3r4.5−42.2%— | 3.5−74.2%— | 28+148%— | 18+62.8%— | 0.5r16−94.5%— | 13—— | 11—— | 11—— | 9.4—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 367−31.5%6.6% | 67−41.0%6.2% | 62−45.6%4.1% | 115−25.9%8.5% | 124*−19.5%7.8% | 113−25.1%7.8% | 113−25.0%8.9% | 155+3.3%8.3% | 154*+3.3%7.0% | 151—6.4% | 151—6.3% | 150—6.2% | 149*—6.6% | |
| Share-based compensation | 1,004+19.6%18.2% | 139*+107%13.0% | 785*+271%52.0% | 14−95.6%1.1% | 66*−71.8%4.2% | 67−63.8%4.6% | 212−26.3%16.7% | 327+15.1%17.6% | 234*−0.2%10.6% | 186—7.9% | 287—12.0% | 284—11.8% | 235*—10.4% | |
| Cash from operating activities | −12,861—−233% | −3,873*—−362% | −3,201*—−212% | −3,227—−239% | −2,560*—−161% | −2,480*—−172% | −2,647*—−209% | −1,642—−88.6% | −1,677*—−76.0% | −1,709*—−72.7% | −1,532*—−63.9% | −2,346—−97.5% | −1,616*—−71.5% | |
| Capital expenditure | −173—−3.1% | −77*—−7.2% | −90*—−6.0% | −5.7—−0.4% | −0.0*—−0.0% | — | −13*—−1.1% | −51—−2.7% | −0.0*—−0.0% | −9.4*—−0.4% | −28*—−1.2% | −41—−1.7% | — | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | — | — | — | — | 0*—0.0% | |
| Cash from investing activities | −173—−3.1% | −77*−2213%−7.2% | −90*—−6.0% | −5.7—−0.4% | −0.0*—−0.0% | 3.6*—0.3% | −13*—−1.1% | −51—−2.7% | −0.0*−100%−0.0% | −9.4*—−0.4% | −28*—−1.2% | −41—−1.7% | 13*—0.6% | |
| Cash from financing activities | 7,914−48.7%143% | 4,070*−56.4%380% | 2,622*−13.1%174% | −119−111%−8.8% | 1,340*−33.8%84.1% | 9,343*+458%646% | 3,019*—238% | 1,032−48.9%55.7% | 2,026*—91.8% | 1,674*—71.2% | −91*—−3.8% | 2,019—83.9% | −85*—−3.8% | |
| Change in cash | −5,119−174%−92.7% | 120*−98.2%11.2% | −669*−287%−44.3% | −3,351—−248% | −1,219*−450%−76.6% | 6,866*—475% | 358*—28.2% | −661—−35.6% | 349*—15.8% | −45*—−1.9% | −1,652*—−68.9% | −368—−15.3% | −1,688*—−74.6% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at bioAffinity Technologies, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Delisting noticeFiling
Delisting notice 1 · Directors and officers 1 · Material agreement 3 · Unregistered share sale 2 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 3
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreementUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Directors and officersShareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 6, 2026
Acquisitions and funding#
1 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How bioAffinity Technologies, Inc. compares in Diagnostics and Research
- Market cap$5 M · higher than 7% of 110
- Revenue$6 M · higher than 12% of 123
- Net margin-279.4% · higher than 5% of 112
- Revenue growth-34.2% · higher than 6% of 89
- Price / sales1.0× · lower than 88% of 85
- Price / book0.7× · lower than 87% of 84
- FCF yield-174.2% · higher than 0% of 66
Peer comparison · Diagnostics and Research
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| bioAffinity Technologies, Inc.🇺🇸 | $5 M | — | -279.4% | -34.2% |
| Thermo Fisher Scientific Inc.🇺🇸 | $253.8 B | 35.9× | 14.9% | +3.9% |
| Danaher Corporation🇺🇸 | $166.7 B | 38.5× | 16.9% | +2.9% |
| WuXi AppTec Co., Ltd.🇨🇳 | $70.4 B | 25.4× | 42.1% | — |
| Natera, Inc.🇺🇸 | $58.7 B | — | -5.7% | +35.9% |
| Siemens Healthineers AG🇩🇪 | $52.8 B | 22.9× | 8.7% | — |
| Lonza Group AG🇨🇭 | $51.9 B | — | -4.2% | — |
| Agilent Technologies, Inc.🇺🇸 | $48.8 B | 33.9× | 19.5% | +6.7% |
| IQVIA Holdings Inc.🇺🇸 | $45.1 B | 32.4× | 8.1% | +5.9% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 28, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at bioAffinity Technologies, Inc.? Verify and update this profile — free
Show bioAffinity Technologies, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.